FRANKLIN, Mass., Feb. 5 /PRNewswire-FirstCall/ -- Echo Therapeutics,
Inc. (OTC Bulletin Board: ECTE), a specialty pharmaceuticals and diabetes
management company, announced today that Patrick T. Mooney, M.D, Chairman
and Chief Executive Officer, will present at the RedChip Small-Cap Investor
Conference on February 7, 2008 at 3:50 pm Mountain Standard Time (5:50 pm
Eastern Standard Time). The conference will be held at the Four Seasons
Resort in Scottsdale, Arizona. A live video webcast of the presentation
will be available on the RedChip Small-Cap Investor Conference website,
http://www.visualwebcaster.com/RedChipfeb2008/. A replay of the webcast and
the corresponding presentation will be available on Echo Therapeutics'
website shortly following the live presentation.
About Echo Therapeutics
Echo Therapeutics is a platform-enabled, specialty pharmaceuticals and
diabetes management company leveraging its expertise in transdermal science
to develop and commercialize non-invasive specialty pharmaceutical products
and medical devices. Echo's Symphony(TM) CTGM System is a next generation
needle- free, wireless, continuous transdermal glucose monitoring (CTGM)
system for diabetes home use and emerging hospital critical care markets.
Symphony is designed to provide on-demand glucose data conveniently,
continuously and cost-effectively. Symphony incorporates Echo's patented
feedback mechanism for optimal skin permeation control and its continuous
transdermal biosensor. With Symphony, Echo is focused on changing the
paradigm of invasive, episodic glucose testing in diabetes home use and
hospital critical care settings. Echo is also marshalling the potential of
its patented AzoneTS(TM) transdermal drug delivery technology to build an
extensive pipeline of advanced topical reformulations of FDA-approved
products in accordance with the FDA's Section 505(b)(2) guidelines. Echo
has submitted a New Drug Application (NDA) to the FDA for the approval of
its lead AzoneTS-based product candidate, Durhalieve(TM), for the treatment
of corticosteroid responsive dermatoses.
Forward-Looking Statements
This press release contains forward-looking information that involves
risks and uncertainties, including statements regarding Echo's development
plans, objectives, expectations and intentions, including, without
limitation, statements regarding the Company's Symphony and AzoneTS product
candidates. Factors that could adversely affect Echo's business and
prospects are described in the Company's filings with the Securities and
Exchange Commission. Echo expressly disclaims any obligation or undertaking
to release publicly any updates or revisions to any such statements to
reflect any change in the Company's expectations or any change in events,
conditions or circumstances on which any such statement is based.
Investor Relations Contacts:
Patrick T. Mooney, M.D.
Chairman & CEO
Echo Therapeutics
508-530-0329
Lilian Stern
Stern Investor Relations
212-362-1200
SOURCE Echo Therapeutics, Inc.
 back to top
Related links:
http://www.visualwebcaster.com/RedChipfeb2008
CONTACT:
Patrick T. Mooney, M.D., Chairman & CEO of
Echo Therapeutics, +1-508-530-0329; or Lilian Stern of Stern
Investor Relations, +1-212-362-1200, for Echo Therapeutics
|
